This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Incyte Corporation (INCY - Analyst Report) reported earnings of 5 cents per share in the second quarter of 2013, below the Zacks Consensus Estimate of 8 cents but above the year-ago earnings of 3 cents per share. The year-over-year rise in earnings was due to higher revenues.
Quarter in Detail
Total revenue in the reported quarter jumped 17.5% to $101.7 million. Revenues were boosted by the increase in Jakafi sales and an inclusion of product royalty revenues. Jakafi, Incyte’s sole marketed product, was launched in the U.S. in Nov 2011, for treating patients suffering from intermediate or high-risk myelofibrosis (MF). Revenues were however short of the Zacks Consensus Estimate of $107 million.
Total revenue comprised net product revenues, product royalty revenues, contract revenues and others.
Incyte recorded net product revenues of approximately $54.1 million from Jakafi sales in the second quarter of 2013, up 82% year over year. Revenues from the drug were up 12% sequentially.
Incyte has a collaborative agreement with Novartis (NVS - Snapshot Report) to market Jakafi outside the U.S. The drug is also approved by the European Commission to treat adults suffering from primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF.
We note that Jakafi is being studied for additional indications. Novartis is currently evaluating Jakafi in two phase III clinical trials (RESPONSE and RELIEF), for the treatment of patients suffering from polycythemia vera (PV). The company intends to submit a supplemental new drug application for Jakafi in the PV indication in the first half of 2014 based on the positive results from the RESPONSE trial.
Jakafi is also being evaluated in a phase II trial in combination with Roche Holding’s (RHHBY) Xeloda for the treatment of refractory metastatic pancreatic cancer. Top-line results from the study are expected soon. The company is looking to expand Jakafi’s label in other oncology indications as well.
Incyte’s product royalty revenues came in at $5.8 million during the reported quarter. The company did not record any product royalty revenues in the year-earlier quarter. Contract revenues declined 26.4% to $41.7 million during the quarter. Other revenues were $39,000, down 50% from the year-ago quarter.
Both research and development (R&D) expenses (up 18.1% to $61.0 million) and selling, general and administrative (SG&A) expenses (up 17.9% to $23.2 million) climbed during the quarter. Incyte’s efforts to develop its pipeline were primarily responsible for the rise in R&D expenses in the second quarter of 2013. Higher costs related to the marketing of Jakafi pushed the SG&A costs up.
Apart from releasing the second quarter 2013 quarterly results, the company also updated its guidance for 2013. The company upped its net product sales guidance for Jakafi to the range of $220–$230 million from the previous range of $210–$225 million. The net sales guidance excludes any product royalty revenues received from Novartis on sales of Jakavi (EU trade name of Jakafi).
We are encouraged by the strong Jakafi sales during the second quarter of 2013. Incyte also has a robust pipeline. Successful development and commercialization of these candidates should drive growth at the company.
Incyte, a biopharma company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks such as Actelion Ltd. (ALIOF) currently look better positioned with a Zacks Rank #1 (Strong Buy).